Organogenesis trial results show safety, efficacy of NuShield for DFUs

Organogenesis Holdings announced the publication of “Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial” in the Journal of Wound Care. “We are pleased this data demonstrates NuShield provides a significant advantage when managing DFUs, a severe medical crisis that often leads to amputations and associated higher mortality rates, especially in underserved populations,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “As a leader in this field, we support CMS’s evidence-based approach to coverage for these serious wounds and believe this large, peer-reviewed published RCT satisfies the requirements for Medicare coverage under the proposed LCDs.”